Unknown

Dataset Information

0

Baseline and Trend of Lymphocyte-to-Monocyte Ratio as Prognostic Factors in Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer Patients Treated with First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.


ABSTRACT: Patients with early-stage lung cancer who have a high baseline lymphocyte-to-monocyte ratio (LMR) have a favorable prognosis. However, the prognostic significance of LMR in patients with advanced-stage EGFR-mutant non-small cell lung cancer (NSCLC) receiving first-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) has not been established. We conducted a retrospective analysis to investigate the influence of LMR on clinical outcomes including progression-free survival (PFS) and overall survival (OS) in EGFR-mutant patients with NSCLC.Of 1310 lung cancer patients diagnosed between January 2011 and October 2013, 253 patients receiving first-line EGFR-TKIs for EGFR-mutant NSCLC were included. The cut-off values for baseline and the 1-month-to-baseline ratio of LMR (MBR), determined by using receiver operating characteristic curves, were 3.29 and 0.63, respectively. Patients were divided into 3 prognostic groups: high LMR and MBR, high LMR or MBR, and low LMR and MBR.The mean patient age was 65.2 years, and 41% were men. The median PFS and OS were 10.3 and 22.0 months, respectively. The PFS in patients with high LMR and MBR, high LMR or MBR, and low LMR and MBR were 15.4, 7.1, and 2.0 months, respectively (p < 0.001), whereas the OS were 32.6, 13.7, and 5.1 months, respectively (p < 0.001).A combination of baseline and trend of LMR can be used to identify patients with a high mortality risk in EGFR-mutant NSCLC patients receiving first-line EGFR-TKIs.

SUBMITTER: Chen YM 

PROVIDER: S-EPMC4552380 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature

altmetric image

Publications

Baseline and Trend of Lymphocyte-to-Monocyte Ratio as Prognostic Factors in Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer Patients Treated with First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.

Chen Yu-Mu YM   Lai Chien-Hao CH   Chang Huang-Chih HC   Chao Tung-Ying TY   Tseng Chia-Cheng CC   Fang Wen-Feng WF   Wang Chin-Chou CC   Chung Yu-Hsiu YH   Wang Yi-Hsi YH   Su Mao-Chang MC   Huang Kuo-Tung KT   Chen Hung-Chen HC   Chang Ya-Chun YC   Lin Meng-Chih MC  

PloS one 20150827 8


<h4>Background</h4>Patients with early-stage lung cancer who have a high baseline lymphocyte-to-monocyte ratio (LMR) have a favorable prognosis. However, the prognostic significance of LMR in patients with advanced-stage EGFR-mutant non-small cell lung cancer (NSCLC) receiving first-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) has not been established. We conducted a retrospective analysis to investigate the influence of LMR on clinical outcomes including progre  ...[more]

Similar Datasets

| S-EPMC4982590 | biostudies-literature
| S-EPMC4773306 | biostudies-literature
| S-EPMC3589701 | biostudies-literature
| S-EPMC7245911 | biostudies-literature
| S-EPMC7656545 | biostudies-literature
| S-EPMC7802134 | biostudies-literature
| S-EPMC2148274 | biostudies-literature
| S-EPMC3311775 | biostudies-literature
| S-EPMC3673302 | biostudies-literature
| S-EPMC2758558 | biostudies-literature